Conduit Pharmaceuticals Inc
CDT5.750USD
+5.370+1413.16%
Handelsschluss 05/20, 16:00（ET）Kurse um 15 Minuten verzögert
7.96MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Conduit Pharmaceuticals Inc Unternehmen
Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.
Unternehmensinformationen
Unternehmens-codeCDT
Name des UnternehmensConduit Pharmaceuticals Inc
IPO-datumFeb 03, 2022
Gegründet am2021
CEODr. Andrew Regan
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 03
Addresse4851 Tamiami Trail North
StadtNAPLES
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl34103
Telefon16464919132
Websitehttps://www.conduitpharma.com/
Unternehmens-codeCDT
IPO-datumFeb 03, 2022
Gegründet am2021
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
2.37K
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
2.09K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
25.00
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
2.37K
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
2.09K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
25.00
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Sat, May 17
Update-Zeit: Sat, May 17
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Sarborg Ltd.
15.65%
Corvus Capital, Ltd.
2.55%
Charles (Faith L.)
1.39%
AQR Capital Management, LLC
0.94%
State Street Global Advisors (US)
0.94%
Other
78.53%
Aktionärsstatistik
Aktionäre
Anteil
Sarborg Ltd.
15.65%
Corvus Capital, Ltd.
2.55%
Charles (Faith L.)
1.39%
AQR Capital Management, LLC
0.94%
State Street Global Advisors (US)
0.94%
Other
78.53%
Art
Aktionäre
Anteil
Corporation
19.06%
Individual Investor
2.72%
Investment Advisor/Hedge Fund
2.22%
Investment Advisor
1.75%
Family Office
0.26%
Research Firm
0.03%
Hedge Fund
0.03%
Other
73.93%
Institutionelle Beteiligung
Update-Zeit: Mon, Mar 3
Update-Zeit: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
106
2.58M
25.94%
+1.87M
2024Q4
130
594.90K
17.01%
-86.94K
2024Q3
124
660.87K
58.37%
-5.97M
2024Q2
107
6.72M
81.00%
+6.04M
2024Q1
84
6.70M
79.51%
+6.03M
2023Q4
75
648.88K
85.40%
+35.12K
2023Q3
62
611.37K
80.63%
+498.71K
2023Q2
55
24.32K
82.28%
-88.18K
2023Q1
54
29.65K
100.40%
-91.89K
2022Q4
43
121.06K
86.60%
+3.67K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Corvus Capital, Ltd.
302.26K
3.17%
--
--
Dec 04, 2024
Charles (Faith L.)
50.05K
0.52%
+46.63K
+1.37K%
Mar 30, 2025
AstraZeneca PLC
95.05K
1%
+95.05K
--
Aug 07, 2024
Lewis-Hall (Freda C)
77.19K
0.81%
+47.61K
+160.94%
Mar 30, 2025
Murphy Canyon Acquisition Sponsor LLC
40.15K
0.42%
+32.61K
+432.53%
Sep 22, 2023
Farley (Chele Chiavacci)
35.54K
0.37%
+32.02K
+911.01%
Mar 30, 2025
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Datum
Art
Verhältnis
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
